ASTREMIHA THERAPEUTICS develops
a new class of broad-spectrum antivirals

Discover, Prevent and Cure

About Us

Description of image According to the WHO, infectious diseases are among the top three leading causes of death worldwide. ASTREMIHA Therapeutics is developing broad-spectrum antivirals aimed at blocking viral replication and strengthening the immune system to combat infections. These next-generation antivirals will address urgent and priority health needs such as AIDS and long COVID, with innovative preventive and curative properties.

Our Team

Teams & Investors: Our team embodies four essential qualities: Ambition, Creativity, Talent, and a Goal-oriented mindset.

Founders:

Mireille Laforge

Mireille Laforge

PhD, HDR, CR CNRS, CSO

Founder

I discovered broad-spectrum antiviral drugs with immune modulation and research immunometabolism's role in infectious diseases and neurodevelopmental disorders to develop new diagnostic and treatment strategies.

Pierre Gressens

Pierre Gressens

MD, PhD, DRE INSERM, Co-CSO

Co-Founder

Director of research and clinical initiatives focusing on neurodevelopmental disorders and treatments related to premature birth, with over 400 published articles, contributing significantly to medical science.

Raphael de Saint Exupéry

Raphael de Saint Exupéry

Innovation Management

Co-Founder

MSc in Management, specializing in Data Analysis, Innovation Management, and Pharma Consulting, offering expertise in strategic decision-making and innovative solutions within the pharmaceutical and healthcare industries.

Board Members:

François Rossier

François Rossier

CEO

François Rossier brings diverse professional expertise from defense and interministerial roles to his current positions in private sector as Key Account Director for France and Switzerland, alongside volunteering as Secretary General of Ailes de France Foundation and ambassador for Institut Robert Debré Brain Child Project.

Isabelle Hilali

Isabelle Hilali

Independent Administrator

Combines extensive global executive experience in aerospace, mobile, internet, healthcare, and education sectors with board memberships and scientific committee roles in health and AI. Her leadership has driven innovation and strategic growth, particularly in international markets, contributing significantly to technological advancements and healthcare improvements.

Thierry Roussel

Thierry Roussel

Independent Administrator

Entrepreneur and executive, co-founded Direct Energie and Senioradom, sold multiple companies, now invests in energy, support for vulnerable people, food, and agriculture. His leadership has been instrumental in driving growth and innovation, and he continues to influence the energy and healthcare sectors through strategic investments and advisory roles.

Scientific Advisory Board Members:

Philippe Rouanet De Berchoux

Philippe Rouanet De Berchoux

Medical Advisor

General practitioner and former Armed Forces Health Service director, specializes in strategic health leadership and crisis management.

Bruno Villoutreix

Bruno Villoutreix

Drug Development Advisor

Research director at INSERM, specializes in AI-driven drug development and therapeutic protein design, with notable contributions to cancer treatment and drug repurposing.

Michael Spedding

Michael Spedding

Drug Development Advisor

President of Spedding Research Solutions SAS, focuses on ALS and long COVID drug development, with a prolific pharmacology career, over 230 publications, and 20+ patents.

Nicolas Chomont

Nicolas Chomont

Scientific Advisor, Immunopathology/Infectiology

Associate Professor at the University of Montreal, researches HIV latency and eradication, focusing on the persistence of HIV-infected cells and T lymphocyte proliferation.

Vincent Calvez

Vincent Calvez

Scientific Advisor, Infectiology/Viral Infection

Professor of Clinical Virology at Sorbonne University, leads the Virology Department at Pitié-Salpêtrière Hospital, directs the ANRS Virology Network, and has significant contributions in antiviral and oncology therapeutics.

Our Research

Article Q-VD-OPH

The anti-caspase inhibitor Q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques

This article discusses the development and use of the anti-caspase inhibitor Q-VD-OPH in preventing AIDS disease progression in SIV-infected rhesus macaques.

View details

Our Partners

Paris Bio Santé

Paris Bio Santé

Incubator, Accelerator for innovative business in the field of human health.

Neuro Diderot

NeuroDiderot

NeuroDiderot is a mixed research Unit.

Contact Us

Location Icon

Paris Bio Santé

Faculté de Médecine

Site Cochin

24 Rue du Faubourg Saint-Jacques

75014 Paris, Île-de-France

Transport Icon

RER B : Port-Royal

Métro Ligne 6 : Saint-Jacques

Bus : 91-83

Find us